Most commonly, KRT17 is overexpressed in cancers (including cervical, oral, ovarian, gastric, lung and pancreatic cancers), and this increased expression is related to adverse outcomes [10,13,14,15,16,17,24,25]. This evidence concerns the gene KRT17 and pancreatic neoplasm.